World Pharma AI · London
2027.

Registration & Networking Breakfast

Opening Keynote

Panel Discussion

From Target to Candidate: Scaling AI-Driven Drug Discovery

• —Where is AI shortening hit-to-lead and candidate selection, and what has reached the clinic?
• —How are UK data assets, including UK Biobank and Genomics England, changing target identification?
• —How do pharma companies and AI-native biotechs structure partnerships, manage IP and judge success?

Panel Discussion

Smarter Clinical Trials: AI in Design, Recruitment and Execution

• —Protocol optimisation, digital twins and synthetic control arms: what evidence will regulators accept?
• —Finding patients faster through NHS data, DigiTrials and real-world evidence.
• —AI-generated protocols, consent forms and study reports: where must human review and sign-off remain?

Morning Networking Break

Panel Discussion

Building the AI Operating Model and Workforce

• —Why do so many generative AI pilots stall, and what have successful programmes done differently?
• —Central AI teams or teams embedded across the business: how should governance, funding and accountability work?
• —Building AI fluency across R&D, clinical, regulatory and commercial functions.

Spotlight Presentation

Fireside Chat

From AI Hype to Enterprise Value — What Is Actually Working in Pharma?

Networking Lunch

Panel Discussion

AI in Commercial & Medical Affairs: From Copilots to Autonomous Engagement

• —How is AI changing HCP engagement and field force productivity?
• —Where can agentic AI support MSLs, medical information and customer engagement?
• —What constitutes measurable commercial return?
• —How should AI-generated content be governed under the ABPI Code and PMCPA requirements?

Spotlight Presentation

Afternoon Break

Panel Discussion

Can Pharma Scale AI Without Exposing Its Most Valuable Data?

• —How can companies make R&D, clinical and commercial data useful for AI while protecting patient information and intellectual property?
• —Who can access data when AI tools connect pharma companies, CROs, NHS organisations and technology partners?
• —What security and data governance checks are needed before an AI pilot reaches enterprise scale?
• —How does the risk change when an AI agent can retrieve information and take action across systems?

Panel Discussion

Agentic AI Across Regulatory, Safety and Medical Writing

• —Where are agents being deployed in submissions, medical review and pharmacovigilance, and what results can companies demonstrate?
• —Which actions can be automated, and where must a person review, approve and remain accountable?
• —How can companies validate, monitor and control agents in a GxP environment?
• —How are teams applying the FDA and EMA’s January 2026 guiding principles of good AI practice?

Closing Keynote

Drinks Reception